Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation

an open-label phase 2 trial

Takehiko Mori, Yoshinobu Kanda, Katsuto Takenaka, Shinichiro Okamoto, Jun Kato, Junya Kanda, Goichi Yoshimoto, Hisashi Gondo, Sayaka Doi, Masaki Inaba, Yoshihisa Kodera

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety and tolerability of ASP0113 in Japanese patients undergoing HCT for hematologic disorders. Ten patients aged 22–61 years were enrolled; nine received at least one dose of ASP0113. Six patients received all five doses of ASP0113 5 mg at intervals before and after HCT. Pre-emptive antiviral therapy was allowed. One patient died following relapse of primary disease. All patients had serious adverse events deemed unrelated to ASP0113. CMV viremia (assessed by CMV antigenemia) occurred in seven patients, who then received anti-CMV therapy. No patients developed CMV end-organ disease. Adverse events associated with ASP0113 injection included pyrexia (three patients), skin reactions [injection site pain, injection site tenderness, and erythema (two patients each); and rash, injection site erythema, injection site induration, and injection site swelling (one patient each)], and hyperuricemia (one patient). ASP0113 was well tolerated in Japanese HCT recipients. Further studies should evaluate its efficacy and safety. ClinicalTrials.gov Identifier: NCT01903928.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalInternational journal of hematology
Volume105
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Cytomegalovirus Vaccines
DNA Vaccines
Cell Transplantation
Safety
Cytomegalovirus
Injections
Erythema
Hyperuricemia
Viremia
Phosphoproteins
Cytomegalovirus Infections
Humoral Immunity
Exanthema
Cellular Immunity

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation : an open-label phase 2 trial. / Mori, Takehiko; Kanda, Yoshinobu; Takenaka, Katsuto; Okamoto, Shinichiro; Kato, Jun; Kanda, Junya; Yoshimoto, Goichi; Gondo, Hisashi; Doi, Sayaka; Inaba, Masaki; Kodera, Yoshihisa.

In: International journal of hematology, Vol. 105, No. 2, 01.02.2017, p. 206-212.

Research output: Contribution to journalArticle

Mori, Takehiko ; Kanda, Yoshinobu ; Takenaka, Katsuto ; Okamoto, Shinichiro ; Kato, Jun ; Kanda, Junya ; Yoshimoto, Goichi ; Gondo, Hisashi ; Doi, Sayaka ; Inaba, Masaki ; Kodera, Yoshihisa. / Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation : an open-label phase 2 trial. In: International journal of hematology. 2017 ; Vol. 105, No. 2. pp. 206-212.
@article{b0470800f06846f99caa40309fa8e4b1,
title = "Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial",
abstract = "Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety and tolerability of ASP0113 in Japanese patients undergoing HCT for hematologic disorders. Ten patients aged 22–61 years were enrolled; nine received at least one dose of ASP0113. Six patients received all five doses of ASP0113 5 mg at intervals before and after HCT. Pre-emptive antiviral therapy was allowed. One patient died following relapse of primary disease. All patients had serious adverse events deemed unrelated to ASP0113. CMV viremia (assessed by CMV antigenemia) occurred in seven patients, who then received anti-CMV therapy. No patients developed CMV end-organ disease. Adverse events associated with ASP0113 injection included pyrexia (three patients), skin reactions [injection site pain, injection site tenderness, and erythema (two patients each); and rash, injection site erythema, injection site induration, and injection site swelling (one patient each)], and hyperuricemia (one patient). ASP0113 was well tolerated in Japanese HCT recipients. Further studies should evaluate its efficacy and safety. ClinicalTrials.gov Identifier: NCT01903928.",
author = "Takehiko Mori and Yoshinobu Kanda and Katsuto Takenaka and Shinichiro Okamoto and Jun Kato and Junya Kanda and Goichi Yoshimoto and Hisashi Gondo and Sayaka Doi and Masaki Inaba and Yoshihisa Kodera",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s12185-016-2110-3",
language = "English",
volume = "105",
pages = "206--212",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation

T2 - an open-label phase 2 trial

AU - Mori, Takehiko

AU - Kanda, Yoshinobu

AU - Takenaka, Katsuto

AU - Okamoto, Shinichiro

AU - Kato, Jun

AU - Kanda, Junya

AU - Yoshimoto, Goichi

AU - Gondo, Hisashi

AU - Doi, Sayaka

AU - Inaba, Masaki

AU - Kodera, Yoshihisa

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety and tolerability of ASP0113 in Japanese patients undergoing HCT for hematologic disorders. Ten patients aged 22–61 years were enrolled; nine received at least one dose of ASP0113. Six patients received all five doses of ASP0113 5 mg at intervals before and after HCT. Pre-emptive antiviral therapy was allowed. One patient died following relapse of primary disease. All patients had serious adverse events deemed unrelated to ASP0113. CMV viremia (assessed by CMV antigenemia) occurred in seven patients, who then received anti-CMV therapy. No patients developed CMV end-organ disease. Adverse events associated with ASP0113 injection included pyrexia (three patients), skin reactions [injection site pain, injection site tenderness, and erythema (two patients each); and rash, injection site erythema, injection site induration, and injection site swelling (one patient each)], and hyperuricemia (one patient). ASP0113 was well tolerated in Japanese HCT recipients. Further studies should evaluate its efficacy and safety. ClinicalTrials.gov Identifier: NCT01903928.

AB - Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety and tolerability of ASP0113 in Japanese patients undergoing HCT for hematologic disorders. Ten patients aged 22–61 years were enrolled; nine received at least one dose of ASP0113. Six patients received all five doses of ASP0113 5 mg at intervals before and after HCT. Pre-emptive antiviral therapy was allowed. One patient died following relapse of primary disease. All patients had serious adverse events deemed unrelated to ASP0113. CMV viremia (assessed by CMV antigenemia) occurred in seven patients, who then received anti-CMV therapy. No patients developed CMV end-organ disease. Adverse events associated with ASP0113 injection included pyrexia (three patients), skin reactions [injection site pain, injection site tenderness, and erythema (two patients each); and rash, injection site erythema, injection site induration, and injection site swelling (one patient each)], and hyperuricemia (one patient). ASP0113 was well tolerated in Japanese HCT recipients. Further studies should evaluate its efficacy and safety. ClinicalTrials.gov Identifier: NCT01903928.

UR - http://www.scopus.com/inward/record.url?scp=84992702656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992702656&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-2110-3

DO - 10.1007/s12185-016-2110-3

M3 - Article

VL - 105

SP - 206

EP - 212

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -